Keyphrases
Lung Cancer
100%
Phase II Trial
100%
Clinical Cancer Research
100%
Annual Review
100%
Carboplatin
60%
Paclitaxel
60%
Gefitinib
60%
Growth Factor Receptor Tyrosine Kinase
60%
Kinase mutation
60%
Response Rate
40%
Progression-free Survival
40%
Overall Survival
40%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
40%
Surgical Resection
40%
Adjuvant Chemotherapy
40%
Cetuximab
40%
Platinum Therapy
40%
Placebo
20%
High Dose
20%
No Significant Difference
20%
Positron Emission Tomography
20%
Chemoradiotherapy
20%
Thoracotomy
20%
Patient Demographics
20%
Brain Metastases
20%
Pemetrexed
20%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
20%
Prophylactic Cranial Irradiation
20%
Nonsquamous Histology
20%
Overall Survival of Patients
20%
First-line Regimen
20%
Overall Survival Benefit
20%
Extrathoracic Metastasis
20%
Maintenance Pemetrexed
20%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Lung Cancer
100%
Clinical Research
100%
Epidermal Growth Factor Receptor
75%
Paclitaxel
75%
Carboplatin
75%
Gefitinib
75%
Progression Free Survival
50%
Chemotherapy
50%
Non Small Cell Lung Cancer
50%
Cetuximab
50%
Pemetrexed
50%
Placebo
25%
Chemoradiation Therapy
25%
Brain Metastasis
25%
Small Cell Lung Cancer
25%
Medicine and Dentistry
Lung Cancer
100%
Arm
100%
Clinical Research
100%
Overall Survival
57%
Carboplatin
42%
Paclitaxel
42%
Epidermal Growth Factor Receptor
42%
Gefitinib
42%
Progression Free Survival
28%
Non Small Cell Lung Cancer
28%
Adjuvant Chemotherapy
28%
Cetuximab
28%
Pemetrexed
28%
Surgery
28%
Positron Emission Tomography
14%
Metastatic Carcinoma
14%
Placebo
14%
Drug Megadose
14%
Thoracotomy
14%
Patient Population
14%
Chemoradiotherapy
14%
Brain Metastasis
14%
Small Cell Lung Cancer
14%
Prophylactic Cranial Irradiation
14%